Stoke Therapeutics Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases

Reuters01-12

Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases

Stoke Therapeutics Inc. presented updates on its pipeline of RNA-based medicines targeting diseases caused by protein insufficiency. The company highlighted progress in its lead program, zorevunersen, for Dravet syndrome, noting that Phase 3 enrollment is underway with completion expected in the second quarter of 2026 and a data readout anticipated in mid-2027 to support a potential NDA filing. Additional updates included the initiation of a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the UK and Europe, and ongoing lead optimization to identify a clinical candidate for SYNGAP1-related disorders in 2026. Stoke reported a strong balance sheet with approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and outlined continued investment in research and platform expansion. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602557755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 03:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602557755","market":"us","top_or_hot":-1,"title":"Stoke Therapeutics Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Stoke Therapeutics Inc. presented updates on its pipeline of RNA-based medicines targeting diseases caused by protein insufficiency. The company highlighted progress in its lead program, zorevunersen, for Dravet syndrome, noting that Phase 3 enrollment is underway with completion expected in the second quarter of 2026 and a data readout anticipated in mid-2027 to support a potential NDA filing. Additional updates included the initiation of a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the UK and Europe, and ongoing lead optimization to identify a clinical candidate for SYNGAP1-related disorders in 2026. Stoke reported a strong balance sheet with approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and outlined continued investment in research and platform expansion. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stoke Therapeutics Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStoke Therapeutics Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 03:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Stoke Therapeutics Inc. presented updates on its pipeline of RNA-based medicines targeting diseases caused by protein insufficiency. The company highlighted progress in its lead program, zorevunersen, for Dravet syndrome, noting that Phase 3 enrollment is underway with completion expected in the second quarter of 2026 and a data readout anticipated in mid-2027 to support a potential NDA filing. Additional updates included the initiation of a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the UK and Europe, and ongoing lead optimization to identify a clinical candidate for SYNGAP1-related disorders in 2026. Stoke reported a strong balance sheet with approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and outlined continued investment in research and platform expansion. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL8HfSmx:1","article_id":"2602557755","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602557755","pubTimestamp":1768158255,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Stoke Therapeutics Inc. presented updates on its pipeline of RNA-based medicines targeting diseases caused by protein insufficiency. The company highlighted progress in its lead program, zorevunersen, for Dravet syndrome, noting that Phase 3 enrollment is underway with completion expected in the second quarter of 2026 and a data readout anticipated in mid-2027 to support a potential NDA filing. Additional updates included the initiation of a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy  in the UK and Europe, and ongoing lead optimization to identify a clinical candidate for SYNGAP1-related disorders in 2026. Stoke reported a strong balance sheet with approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and outlined continued investment in research and platform expansion. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","STOK":"Stoke Therapeutics, Inc."},"translate_title":"Stoke Therapeutics展示了Dravet综合征和罕见遗传疾病的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":0.9},"content_text":"Stoke Therapeutics Showcases Pipeline Advancements for Dravet Syndrome and Rare Genetic Diseases\n    \n\n        Stoke Therapeutics Inc. presented updates on its pipeline of RNA-based medicines targeting diseases caused by protein insufficiency. The company highlighted progress in its lead program, zorevunersen, for Dravet syndrome, noting that Phase 3 enrollment is underway with completion expected in the second quarter of 2026 and a data readout anticipated in mid-2027 to support a potential NDA filing. Additional updates included the initiation of a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the UK and Europe, and ongoing lead optimization to identify a clinical candidate for SYNGAP1-related disorders in 2026. Stoke reported a strong balance sheet with approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and outlined continued investment in research and platform expansion. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602557755","isCrawlerRequest":true}